Acurx Pharmaceuticals, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.42 | $-0.53 | -26.2% | Miss |
| Q12026 FY2026 | $-0.59 | $-0.62 | -5.1% | Miss |
| Q42025 FY2025 | $-1.01 | $-0.31 | +69.3% | Beat |
Back to ACXP overview · ACXP holders · ACXP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.